AstraZeneca Acquires T Cell Biotech TeneoTwo in $1.27 Billion Deal

AstraZeneca is expanding into the T cell engager market with its acquisition of TeneoTwo. The small biotech just recently sold off two of its sub-companies to Abbvie and Amgen, as well as raising $60 million in funding to maintain some of the its remaining operations under its control. Astrazeneca is purchasing the TeneoTwo to pick up one of its main drugs.

According to , “TNB-486 targets both CD19 (a cancer antigen) and CD3 (which hooks in the T cell), and is in a dose-escalation study involving relapsed and refractory B cell non-Hodgkin lymphoma patients. Close to 30 patients have already been enrolled, and the first round of data is expected to come out at ASH or ASCO.”

To read more, click here.

(Source: Endpoints News, July 1, 2022)